[EN] DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS DIHYDROPYRAZOLOPYRIMIDINONE UTILISÉS EN TANT QU'EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2016192083A1
公开(公告)日:2016-12-08
The present invention is directed to dihydropyrazolopyrimidinonecompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
A new method for the formation of 1,1‐difluoroethyl copper species (“CuCF2CH3”) with 1,1‐difluoroethylsilane (TMSCF2CH3) has been developed. The “CuCF2CH3” species can be applied to the efficient 1,1‐difluoroethylation of diaryliodonium salts under mild conditions, affording (1,1‐difluoroethyl)arenes in good to excellent yields. This convenient procedure tolerates a wide range of functional groups
SUBSTITUTED PYRAZOLE COMPOUNDS CONTAINING PYRIMIDINE, THE PREPARATION AND APPLICATION THEREOF
申请人:Shenyang Sinochem Agrochemicals R&D Co., Ltd.
公开号:EP3702355A1
公开(公告)日:2020-09-02
Disclosed are substituted pyrazole compounds containing pyrimidinyl as shown in Formula I:
The definitions of each of the substituents can be seen in the description.
The compounds of present invention have a good spectrum of bactericidal, insecticidal and acaricidal activity,and have good control effect on downy mildew of cucumber, powdery mildew of wheat, corn rust, rice blast, cucumber anthracnosis and the like. The compounds of present invention also show good insecticidal activity.
所公开的是含有如式 I 所示嘧啶基的取代吡唑化合物:
各取代基的定义见说明。
本发明化合物具有良好的杀菌、杀虫和杀螨活性谱,对黄瓜霜霉病、小麦白粉病、玉米锈病、稻瘟病、黄瓜炭疽病等具有良好的防治效果。本发明的化合物还具有良好的杀虫活性。
Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
申请人:Merck Sharp & Dohme Corp.
公开号:US10174037B2
公开(公告)日:2019-01-08
The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.